210 related articles for article (PubMed ID: 37967200)
1. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
[TBL] [Abstract][Full Text] [Related]
4. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
[TBL] [Abstract][Full Text] [Related]
5. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
10. Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.
Sulsenti R; Frossi B; Bongiovanni L; Cancila V; Ostano P; Fischetti I; Enriquez C; Guana F; Chiorino G; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
Front Immunol; 2021; 12():622001. PubMed ID: 33737929
[TBL] [Abstract][Full Text] [Related]
11. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
[No Abstract] [Full Text] [Related]
13. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
[TBL] [Abstract][Full Text] [Related]
14. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
Zhang A; Lau NA; Wong A; Brown LG; Coleman IM; De Sarkar N; Li D; DeLucia DC; Labrecque MP; Nguyen HM; Conner JL; Dumpit RF; True LD; Lin DW; Corey E; Alumkal JJ; Nelson PS; Morrissey C; Lee JK
Cancer Res Commun; 2023 Nov; 3(11):2358-2374. PubMed ID: 37823778
[TBL] [Abstract][Full Text] [Related]
17. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
